Key result
Aspirin withdrawal in thrombocythaemia is linked to microvascular thrombosis preceded by a ~30-fold thromboxane increase.
Why the study?
The pathogenesis of arterial thrombotic events in patients with polycythaemia vera and essential thrombocythaemia is not clearly understood but may involve platelet function abnormalities and increased thromboxane formation.
Does low-dose aspirin inhibit platelet thromboxane formation and prevent arterial microvascular thrombosis in patients with thrombocythaemia?
Does low-dose aspirin inhibit platelet thromboxane formation and prevent arterial microvascular thrombosis in patients with thrombocythaemia?
In patients with thrombocythaemia, increased platelet thromboxane formation precedes arterial microvascular thrombosis, providing a mechanistic rationale for low-dose aspirin therapy.
Answers are grounded in this paper and cite their sources.
Platelet thromboxane surge precedes microvascular thrombosis in ET/PV; supports aspirin use but hypothesis-generating pending larger trials.
The clinical course of patients with polycythaemia vera (PV) and essential thrombocythaemia (ET) is frequently complicated by arterial thrombotic events. The pathogenesis is not clearly understood but attributed to abnormalities in platelet function. An increase in platelet thromboxane formation has been described in the majority of asymptomatic patients with thrombocythaemia, probably reflecting spontaneous platelet activation in vivo. In the present study we prospectively investigated whether an increase in platelet thromboxane formation actually precedes arterial microvascular thrombosis. In addition, we studied the effect of selective inhibition of platelet thromboxane formation on clinical outcome by reinstitution of low-dose aspirin (50 mg/ d). Six ET patients and one PV patient participated in this study. Within 10 d after withdrawal of aspirin, three patients developed arterial microvascular thrombosis of extremities (erythromelalgia), which was preceded by a 3-30-fold increase in urinary thromboxane excretion as compared with patients who remained asymptomatic. The increased urinary thromboxane excretion and clinical signs could be inhibited by a platelet-specific aspirin regimen of 50 mg/d without affecting vascular cyclooxygenase, indicating that platelets were the main source of the increased thromboxane generation. These data suggest that in symptomatic patients an enhanced formation of thromboxane by platelets, reflecting platelet activation in vivo, precedes the development of arterial microvascular thrombosis. These data provide a rationale for using low-dose aspirin as an antithrombotic agent in thrombocythaemia.
No takes yet. Share an insight, caveat, or question.
Genderen et al. (1999) studied Polycythaemia vera (PV) and essential thrombocythaemia (ET) (n=7). Low-dose aspirin vs. Aspirin withdrawal was evaluated on Arterial microvascular thrombosis of extremities (erythromelalgia) and urinary thromboxane excretion. In patients with thrombocythaemia, arterial microvascular thrombosis following aspirin withdrawal was preceded by a 3-30-fold increase in urinary thromboxane excretion.
Synapse has enriched 10 related papers. Consider them for comparative context: